Interleukin 10 gene promoter polymorphism and risk of diffuse large B cell lymphoma (DLBCL)

Abstract

PurposeGiven the importance of understanding the genetic variations involved in the pathogenesis of non-Hodgkin’s lymphoma (NHL), this work was designed to study the impact of IL-10 (−1082 G/A; rs1800896 and −819 C/T; rs1800871) gene promoter polymorphism on susceptibility of Egyptians to diffuse large B cell lymphoma (DLBCL); the major type of NHL. To the best of our knowledge, this study is the first one that examines IL-10 promoter polymorphism in DLBCL in Egyptians. MethodsGenotyping polymorphism is performed using sequence-specific primers polymerase chain reaction (SSP-PCR) in 100 Egyptian DLBCL patients and 119 normal controls. Circulating plasma levels of IL-10 were measured using Enzyme-linked immunosorbent assay (ELISA). ResultsInsignificant change in IL-10 (−1082 and −819) genotypes was recorded. Although A allele is slightly decreased in DLBCL patients, it did not reach statistical significance. GT haplotype was significantly elevated (P<0.05) in NHL patients. A significant linkage disequilibrium between the −1082 and −819 SNPs with D′=0.596 and r2=0.1032 (P<0.001) was demonstrated. Significantly increased plasma IL-10 (P<0.01) was found which is positively correlated (r=0.307; P<0.01) with the disease. ConclusionsTaken together, our findings demonstrated that IL-10 promoter gene polymorphism (−1082 and −819) may not have an influence on the clinical outcome of DLBCL, especially in terms of overall secretion level. Further investigations of other cytokine gene polymorphisms will lead to a better understanding of the disease’s biological background.